FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL™ Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis

Lyon – March 18, 2005 – Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend licensure of ADACEL™ (Tetanus Toxoid and Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) Vaccine for protection against tetanus, diphtheria and pertussis in adolescents and adults aged 11-64 years.

For mer informasjon, les vedlagte pressemelding i PDF-format.